Boston Scientific Corporation (BSX) achieved a milestone with the recent FDA approval for its AGENT Drug-Coated Balloon (DCB). This marks the first drug-coated coronary balloon available in the United States.This approval signals a key advancement in the treatment landscape for coronary in-stent restenosis (ISR), a challenging condition characterized by the narrowing of stented vessels due to plaque or scar tissue formation. With this, Boston Scientific is expected to broaden its Interventional Cardiology ( ...